Therefore, the primary objective of this study is to investigate how public health insurance coverage of the first breast cancer targeted therapy contributed to the changes in the refusal of physician-recommended treatment among HER2-positive breast cancer patients and identify other current barriers to patient access to innovative medicines. Here, ERBB2 is linked to breast cancer.